2023
Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19 Vaccines Among Nursing Home Residents — National Healthcare Safety Network, United States, December 2023
Reses H, Dubendris H, Haas L, Barbre K, Ananth S, Rowe T, Mothershed E, Hall E, Wiegand R, Lindley M, Meyer S, Patel S, Benin A, Kroop S, Srinivasan A, Bell J. Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19 Vaccines Among Nursing Home Residents — National Healthcare Safety Network, United States, December 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 1371-1376. PMID: 38127673, PMCID: PMC10754267, DOI: 10.15585/mmwr.mm7251a3.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusNursing home residentsNational Healthcare Safety NetworkRespiratory virus seasonHome residentsVaccination coverageRespiratory virusesSyncytial virusCDC's National Healthcare Safety NetworkCOVID-19COVID-19 vaccination coverageHuman Services (HHS) regionsCOVID-19 vaccineSARS-CoV-2RSV vaccineSevere complicationsRespiratory illnessSevere outcomesNursing homesEligible residentsVaccinationInfluenzaSafety NetworkOlder adultsVaccine
2021
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021
Nanduri S, Pilishvili T, Derado G, Soe M, Dollard P, Wu H, Li Q, Bagchi S, Dubendris H, Link-Gelles R, Jernigan J, Budnitz D, Bell J, Benin A, Shang N, Edwards J, Verani J, Schrag S. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021. MMWR Morbidity And Mortality Weekly Report 2021, 70: 1163-1166. PMID: 34437519, PMCID: PMC8389386, DOI: 10.15585/mmwr.mm7034e3.Peer-Reviewed Original ResearchConceptsNational Healthcare Safety NetworkSARS-CoV-2 infectionNursing home residentsLong-term care facility residentsMRNA COVID-19 vaccineCOVID-19 vaccineVaccine effectivenessCare facility residentsHome residentsDelta variantPfizer-BioNTechModerna vaccineMRNA vaccinesFacility residentsNursing homesCDC's National Healthcare Safety NetworkPreventing SARS-CoV-2 InfectionSevere COVID-19-associated outcomesVaccine-induced immunityNursing home staff membersProtective immune responseCOVID-19 prevention strategiesWeekly reportsEmergency use authorizationSkilled nursing facilitiesRates of COVID-19 Among Residents and Staff Members in Nursing Homes — United States, May 25–November 22, 2020
Bagchi S, Mak J, Li Q, Sheriff E, Mungai E, Anttila A, Soe M, Edwards J, Benin A, Pollock D, Shulman E, Ling S, Moody-Williams J, Fleisher L, Srinivasan A, Bell J. Rates of COVID-19 Among Residents and Staff Members in Nursing Homes — United States, May 25–November 22, 2020. MMWR Morbidity And Mortality Weekly Report 2021, 70: 52-55. PMID: 33444301, PMCID: PMC7808710, DOI: 10.15585/mmwr.mm7002e2.Peer-Reviewed Original ResearchConceptsNational Healthcare Safety NetworkNursing home residentsCOVID-19 casesHome residentsHigh riskNursing homesCDC's National Healthcare Safety NetworkCOVID-19Certain underlying medical conditionsSARS-CoV-2 transmissionUnderlying medical conditionsNursing home staff membersCoronavirus disease 2019 (COVID-19) pandemicHuman Services (HHS) regionsSARS-CoV-2Disease 2019 pandemicStaff membersHome staff membersCOVID-19 ratesCOVID-19 incidenceHigh-risk exposureSevere outcomesCongregate settingsMedical conditionsGeneral population
2009
Veterans' attitudes to influenza vaccination in the setting of shortage of vaccine, 2004-2005
Benin AL, Learsy-Cahill D, Das R, Kancir S, Welch B, Martinello RA. Veterans' attitudes to influenza vaccination in the setting of shortage of vaccine, 2004-2005. Human Vaccines & Immunotherapeutics 2009, 5: 237-241. PMID: 18948733, DOI: 10.4161/hv.5.4.6808.Peer-Reviewed Original ResearchConceptsElderly veteransAdministration HospitalHigh-risk criteriaVeterans Administration HospitalProportion of veteransUnvaccinated participantsInfluenza vaccinationHigh riskVaccinationVeterans' attitudesVaccineInfluenzaVeteransMore participantsRandom sampleSmall proportionParticipantsAltruistic reasonsQualitative interviewsHospitalProportionUrgencyDose
2007
Risk Factors for Invasive Pneumococcal Disease among Navajo Adults
Watt J, O'Brien K, Benin A, McCoy S, Donaldson C, Reid R, Schuchat A, Zell E, Hochman M, Santosham M, Whitney C. Risk Factors for Invasive Pneumococcal Disease among Navajo Adults. American Journal Of Epidemiology 2007, 166: 1080-1087. PMID: 17693393, DOI: 10.1093/aje/kwm178.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlcoholismAnalysis of VarianceBody Mass IndexCase-Control StudiesFemaleHeart FailureHumansIndians, North AmericanKidney Failure, ChronicMaleMiddle AgedMultivariate AnalysisPneumococcal InfectionsPopulation SurveillanceProspective StudiesRisk FactorsSocioeconomic FactorsStreptococcus pneumoniaeSurveys and QuestionnairesUnited StatesConceptsInvasive pneumococcal diseaseChronic renal failureCongestive heart failureBody mass indexNavajo adultsGeneral US populationRisk factorsRenal failureSelf-reported alcohol useHeart failurePneumococcal diseaseMass indexRisk of IPDUS populationAlcohol useActive laboratory surveillanceModifiable risk factorsMedical record reviewPopulation attributable fractionFinal multivariable analysisCase-control studyMultivariable analysisRecord reviewAttributable fractionHigh prevalence
2006
Influenza Vaccination as Secondary Prevention for Cardiovascular Disease A Science Advisory From the American Heart Association/American College of Cardiology
Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, Dunbar S, Krumholz HM. Influenza Vaccination as Secondary Prevention for Cardiovascular Disease A Science Advisory From the American Heart Association/American College of Cardiology. Journal Of The American College Of Cardiology 2006, 48: 1498-1502. PMID: 17010820, DOI: 10.1016/j.jacc.2006.09.004.Peer-Reviewed Original ResearchConceptsSecondary preventionCardiovascular diseaseCardiovascular conditionsAmerican CollegeAmerican Heart Association/American CollegeInfluenza vaccination coverage levelsInfluenza vaccination coverage ratesComprehensive secondary preventionAtherosclerotic vascular diseaseVaccination coverage ratesRandomized clinical trialsAmerican Heart AssociationVaccination coverage levelsCardiovascular morbidityCause mortalityInfluenza immunizationInfluenza vaccinationCohort studyInfluenza seasonInfluenza vaccineScience AdvisoryHeart AssociationAnnual vaccinationVascular diseaseClinical trials
2005
Delivering Pneumococcal Vaccine to a High Risk Population: The Navajo Experience
Benin AL, Watt JP, O'Brien KL, Reid R, Zell ER, Katz S, Donaldson C, Schuchat A, Santosham M, Whitney CG. Delivering Pneumococcal Vaccine to a High Risk Population: The Navajo Experience. Human Vaccines & Immunotherapeutics 2005, 1: 66-69. PMID: 17038821, DOI: 10.4161/hv.1.2.1562.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedArizonaCross-Sectional StudiesDelivery of Health CareFemaleHumansImmunization ProgramsIndians, North AmericanMaleMiddle AgedNew MexicoPneumococcal InfectionsPneumococcal VaccinesPopulation SurveillanceRiskSample SizeUnited StatesUnited States Public Health ServiceUtahConceptsIndian Health ServiceVaccine indicationsVaccination programHealth servicesPneumococcal polysaccharide vaccineHealthy People 2010High-risk populationPublic health nursingCross-sectional studyNavajo adultsPneumococcal diseasePneumococcal vaccinePolysaccharide vaccineMedical chartsPreventable diseaseHealth nursingPersons 18Home visitsRisk populationsUniversal health insuranceExcellent delivery systemHealth insuranceNavajo patientsVaccineHigh rate
2003
Effectiveness of the 23-Valent Polysaccharide Vaccine against Invasive Pneumococcal Disease in Navajo Adults
Benin AL, O'Brien KL, Watt JP, Reid R, Zell ER, Katz S, Donaldson C, Parkinson A, Schuchat A, Santosham M, Whitney CG. Effectiveness of the 23-Valent Polysaccharide Vaccine against Invasive Pneumococcal Disease in Navajo Adults. The Journal Of Infectious Diseases 2003, 188: 81-89. PMID: 12825175, DOI: 10.1086/375782.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseOverall vaccine effectivenessNavajo adultsPneumococcal diseaseCase patientsControl patientsPolysaccharide vaccineVaccine effectivenessGeneral United States populationSerious pneumococcal diseasePneumococcal polysaccharide vaccineCohort methodologyUnited States populationCase-control setsActive surveillanceObservational studyMedical conditionsPatientsMedical careDiseaseAdultsDiabetesRegression analysisVaccineAlcoholism
2002
Trends in Legionnaires Disease, 1980–1998: Declining Mortality and New Patterns of Diagnosis
Benin A, Benson R, Besser R. Trends in Legionnaires Disease, 1980–1998: Declining Mortality and New Patterns of Diagnosis. Clinical Infectious Diseases 2002, 35: 1039-1046. PMID: 12384836, DOI: 10.1086/342903.Peer-Reviewed Original ResearchConceptsLegionella pneumophila serogroup 1Legionnaires' diseaseUrine antigen testingCases of LDCommunity-acquired casesCase fatality rateCulture-based diagnosisNew diagnostic testsPassive surveillance systemDirect fluorescent antibodyAntigen testingEmpirical therapyNosocomial casesPneumophila serogroup 1Serologic testingOutbreak investigationDisease controlDiagnostic testsDiagnosisSerogroup 1Fluorescent antibodyLegionella isolatesMortalityDiseaseSurveillance system
2001
An Outbreak of Travel-Associated Legionnaires Disease and Pontiac Fever: The Need for Enhanced Surveillance of Travel-Associated Legionellosis in the United States
Benin A, Benson R, Arnold K, Fiore A, Cook P, Williams L, Fields B, Besser R. An Outbreak of Travel-Associated Legionnaires Disease and Pontiac Fever: The Need for Enhanced Surveillance of Travel-Associated Legionellosis in the United States. The Journal Of Infectious Diseases 2001, 185: 237-243. PMID: 11807698, DOI: 10.1086/338060.Peer-Reviewed Original ResearchConceptsLegionnaires' diseasePontiac feverOutbreaks of LDTravel Associated Legionnaires' DiseaseImmunoglobulin M antibodiesLegionella pneumophila serogroup 6Fragment length polymorphism typingIgM seropositivityCohort studyM antibodiesIndex patientsPF casesEnhanced surveillanceSPA exposureOutbreak investigationSerogroup 6DiseaseWhirlpool spaFeverPolymorphism typingOutbreakNew laboratory techniquesLegionellosisSurveillanceEnvironmental investigations